Broadening role for external control arms in clinical trials
News
July 15, 2019
External control arms are moving from theory to practice as drug developers begin to use them to make internal go/no-go decisions for clinical programs and to support regulatory applications. The field is largely split between those drawing on past clinical trials versus real-world data, and at least one company is pushing the approach further by simulating artificial patients to augment control arms in complex, chronic indications like Alzheimer's disease.